Abstract
Background:
Cerebral white matter (WM) injury and stroke are common neuropathological injuries in newborns with congenital heart defects (CHDs) requiring surgery. Previous investigations in Long Evans rat pups subjected to hypoxia–ischemia found that intraperitoneal (i.p.) topiramate (TPM) at 30 mg/kg, but not 50 mg/kg, conferred neuroprotection. In Sprague-Dawley pups, a dose of 30 mg/kg protected against stroke. Concentrations associated with neuroprotective doses were not measured. The aims of this investigation were to determine concentrations associated with neuroprotective doses and to investigate the pharmacokinetics (PK) of i.p. TPM.
Methods:
Concentration–time data following administration of 30 and 50 mg/kg doses were analyzed using nonlinear mixed–effect modeling.
Results:
Mean predicted steady-state maximum and average concentrations following 30 mg/kg TPM were 31.3 and 16.8 μg/ml in Long Evans and 39.9 and 24.4 μg/ml in Sprague-Dawley pups. Mean predicted steady-state maximum and average concentrations following 50 mg/kg TPM were 52.1 and 28.1 μg/ml in Long Evans and 66.5 and 40.6 μg/ml in Sprague-Dawley pups. The apparent clearance (CL/F) and apparent volume of distribution (V/F) were 0.0470 ml/min and 22.2 ml, respectively, for Long Evans and 0.0325 ml/min and 19.7 ml, respectively, for Sprague-Dawley pups.
Conclusion:
TPM concentrations associated with neuroprotective doses were determined. Body size and strain were significant covariates on CL/F and V/F. Results provide targets for future neuroprotection studies.
Similar content being viewed by others
Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
References
Mahle WT, Tavani F, Zimmerman RA, et al. An MRI study of neurological injury before and after congenital heart surgery. Circulation 2002;106(12 Suppl 1):I109–14.
Chen J, Zimmerman RA, Jarvik GP, et al. Perioperative stroke in infants undergoing open heart operations for congenital heart disease. Ann Thorac Surg 2009;88:823–9.
Follett PL, Rosenberg PA, Volpe JJ, Jensen FE . NBQX attenuates excitotoxic injury in developing white matter. J Neurosci 2000;20:9235–41.
Follett PL, Deng W, Dai W, et al. Glutamate receptor-mediated oligodendrocyte toxicity in periventricular leukomalacia: a protective role for topiramate. J Neurosci 2004;24:4412–20.
Liu Y, Barks JD, Xu G, Silverstein FS . Topiramate extends the therapeutic window for hypothermia-mediated neuroprotection after stroke in neonatal rats. Stroke 2004;35:1460–5.
Topamax [Package Insert]. Janssen Pharmaceuticals Inc., Titusville, NJ, 2012.
Novotny E, Renfroe B, Yardi N, et al. Randomized trial of adjunctive topiramate therapy in infants with refractory partial seizures. Neurology 2010;74:714–20.
Filippi L, Poggi C, la Marca G, et al. Oral topiramate in neonates with hypoxic ischemic encephalopathy treated with hypothermia: a safety study. J Pediatr 2010;157:361–6.
Filippi L, la Marca G, Fiorini P, et al. Topiramate concentrations in neonates treated with prolonged whole body hypothermia for hypoxic ischemic encephalopathy. Epilepsia 2009;50:2355–61.
Glass HC, Poulin C, Shevell MI . Topiramate for the treatment of neonatal seizures. Pediatr Neurol 2011;44:439–42.
Anderson BJ, Holford NH . Mechanism-based concepts of size and maturity in pharmacokinetics. Annu Rev Pharmacol Toxicol 2008;48:
303–32.
Andiné P, Sandberg M, Bågenholm R, Lehmann A, Hagberg H . Intra- and extracellular changes of amino acids in the cerebral cortex of the neonatal rat during hypoxic-ischemia. Brain Res Dev Brain Res 1991;64:
115–20.
Benveniste H, Drejer J, Schousboe A, Diemer NH . Elevation of the extracellular concentrations of glutamate and aspartate in rat hippocampus during transient cerebral ischemia monitored by intracerebral microdialysis. J Neurochem 1984;43:1369–74.
Choi DW . Excitotoxic cell death. J Neurobiol 1992;23:1261–76.
Hagberg H, Gilland E, Diemer NH, Andiné P . Hypoxia-ischemia in the neonatal rat brain: histopathology after post-treatment with NMDA and non-NMDA receptor antagonists. Biol Neonate 1994;66:
205–13.
Patsalos PN, Berry DJ, Bourgeois BF, et al. Antiepileptic drugs–best practice guidelines for therapeutic drug monitoring: a position paper by the subcommission on therapeutic drug monitoring, ILAE Commission on Therapeutic Strategies. Epilepsia 2008;49:1239–76.
Topamax [Package Insert]. Janssen Pharmaceuticals Inc., Titusville, NJ, NDA 020505, 1996.
Shank RP, Gardocki JF, Streeter AJ, Maryanoff BE . An overview of the preclinical aspects of topiramate: pharmacology, pharmacokinetics, and mechanism of action. Epilepsia 2000;41 :Suppl 1:S3–9.
Glauser TA, Miles MV, Tang P, Clark P, McGee K, Doose DR . Topiramate pharmacokinetics in infants. Epilepsia 1999;40:788–91.
FDA Topiramate Pediatric Clinical Pharmacology Review. (http://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/DevelopmentResources/ucm129621.pdf.2008).
NONMEM User Manual. In: 7th edn. Dublin, Ireland: ICON Development Solutions, 2010.
Efron B . Bootstrap Methods: Another look at the jacknife. Ann Stat 1979;7:1–26.
Parke J, Holford NH, Charles BG . A procedure for generating bootstrap samples for the validation of nonlinear mixed-effects population models. Comput Methods Programs Biomed 1999;59:19–29.
Post TM, Freijer JI, Ploeger BA, Danhof M . Extensions to the visual predictive check to facilitate model performance evaluation. J Pharmacokinet Pharmacodyn 2008;35:185–202.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Clark, A., Mondick, J., Cloyd, J. et al. Plasma topiramate concentrations resulting from doses associated with neuroprotection against white matter injury and stroke in two strains of rat pups. Pediatr Res 73, 317–324 (2013). https://doi.org/10.1038/pr.2012.194
Received:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1038/pr.2012.194
